神経内分泌腫瘍治療の市場規模・シェア・成長分析 (腫瘍の種類別、治療製品別、部位別、最終用途別、地域別)：産業予測 (2025～2032年)

世界の神経内分泌腫瘍治療の市場規模は、2023年に23億4,000万米ドルと評価され、2024年の24億8,000万米ドルから2032年には38億9,000万米ドルに成長し、予測期間 (2025-2032年) のCAGRは5.8%に達する見通しです。

世界のがん罹患率の上昇、特にカルチノイド腫瘍などの神経内分泌腫瘍 (NET) は、革新的な治療に対する緊急の必要性を強調しています。神経系と内分泌系の両方に由来するこれらのまれな腫瘍は、主に消化管を侵しますが、虫垂、膵臓、直腸、肺などの臓器にも認められます。胃腸の問題から心臓の問題まで、さまざまな症状がNETの複雑さを際立たせています。診断能力の向上や研究開発投資の増加と相まって認知度が高まるにつれ、神経内分泌腫瘍の治療市場は大きく成長する見込みです。この傾向は、予測期間中、新しい治療法の導入や検出方法の改善を通じて、希少悪性腫瘍への取り組みが広がっていることを示しています。

目次

イントロダクション

• 分析目的
• 市場範囲
• 定義

分析手法

• 情報調達
• 二次・一次データの手法
• 市場規模予測
• 市場の想定と制約

エグゼクティブサマリー

• 市場の概要と展望
• 需給動向の分析
• セグメント別の機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析

市場の主な考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場魅力度指数 (2024年)
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• 特許分析
• ケーススタディ

世界の神経内分泌腫瘍治療の市場規模・CAGR：腫瘍の種類別 (2025～2032年)

• 市場概要
• 髄膜腫
• 副腎がん
• カルチノイド腫瘍
• 傍神経節腫
• 褐色細胞腫
• その他

世界の神経内分泌腫瘍治療の市場規模・CAGR：治療製品別 (2025～2032年)

• 市場概要
• ソマトスタチン類似体 (SSA)
• 標的療法
• その他

世界の神経内分泌腫瘍治療の市場規模・CAGR：部位別 (2025～2032年)

• 市場概要
• 肺
• 膵臓
• 結腸
• 小腸
• 直腸
• 胃
• その他

世界の神経内分泌腫瘍治療の市場規模・CAGR：最終用途別 (2025～2032年)

• 市場概要
• 病院
• クリニック
• その他

世界の神経内分泌腫瘍治療の市場規模・CAGR (2025～2032年)

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2024年)
• 主要企業が採用した戦略
• 市場の近年の動向
• 主要企業の市場シェア (2024年)
• 主要企業のプロファイル
  • 企業概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較 (2022～2024年)

主要企業プロファイル

• Novartis AG (スイス)
• Bristol Myers Squibb Company (米国)
• Pfizer Inc. (米国)
• Boehringer Ingelheim International GmbH (ドイツ)
• Hutchison MediPharma Limited (中国)
• AVEO Pharmaceuticals, Inc. (米国)
• Ipsen Pharma (フランス)
• Eli Lilly and Company (米国)
• Exelixis, Inc. (米国)
• Jubilant Pharmova Limited (インド)
• F. Hoffmann-La Roche Ltd (スイス)
• Viatris Inc. (米国)
• Thermo Fisher Scientific Inc. (米国)
• Regeneron Pharmaceuticals, Inc. (米国)
• Sun Pharmaceutical Industries Ltd. (インド)
• Teva Pharmaceutical Industries Ltd. (イスラエル)
• Lupin (インド)
• Exact Sciences Corporation (米国)
• Advanced Accelerator Applications (フランス)
• BioSynthema Inc. (米国)

結論と推奨事項

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.34 billion in 2023 and is poised to grow from USD 2.48 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The global rise in cancer incidence, particularly neuroendocrine tumors (NET) such as carcinoid tumors, underscores an urgent need for innovative treatments. These rare tumors, originating from both the neurological and endocrine systems, primarily affect the gastrointestinal tract but are also found in organs like the appendix, pancreas, rectum, and lungs. Symptoms ranging from gastrointestinal issues to heart problems highlight the complexity of NETs. As awareness increases, coupled with enhanced diagnostic capabilities and rising research and development investments, the treatment market for neuroendocrine tumors is poised for significant growth. This trend is indicative of a broader commitment to addressing rare malignancies through the introduction of new therapies and improved detection methods over the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuroendocrine Tumors Treatment Market Segmental Analysis

Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is poised for growth due to the increasing incidence of neuroendocrine tumors (NET) around the world. Data from the American Society of Clinical Oncology (ASCO) indicates a steady rise in both the incidence and prevalence of these tumors, which significantly influences market dynamics. As more individuals are diagnosed with this rare condition, there is a corresponding increase in the adoption of various treatment medications, thereby further propelling market demand. This trend reflects a growing recognition of neuroendocrine tumors, leading to advancements in treatment options and an overall expansion of the market.

Restraints in the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors (NET) Treatment market faces several restraints that could limit its growth. One significant factor is the potential side effects associated with treatments, which may deter patients from pursuing therapy. Common adverse effects include elevated blood sugar levels, gallstone formation, and mild digestive issues such as bloating and nausea. Additionally, the high costs associated with developing effective treatments and pharmaceuticals can pose a substantial barrier to market expansion. As a result, these financial burdens and the apprehension surrounding treatment-related complications may impede the overall progress of the NET treatment market during the forecast period.

Market Trends of the Global Neuroendocrine Tumors Treatment Market

The global neuroendocrine tumors treatment market is witnessing a significant upward trend, primarily driven by the increasing adoption of somatostatin analogs (SSAs). As these therapeutic agents effectively inhibit tumor growth, alleviate symptoms, and improve biomarker profiles, they have emerged as the preferred choice for managing neuroendocrine tumors. Their proven safety and efficacy contribute to dominating the revenue share in the market. Additionally, ongoing clinical trials and potential approvals of newer SSAs are expected to further fuel market growth. The landscape is evolving, with rising patient awareness and advancements in treatment protocols, making it a promising arena for stakeholders in the healthcare sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2025-2032)

• Market Overview
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2025-2032)

• Market Overview
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2025-2032)

• Market Overview
• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Others

Global Neuroendocrine Tumors Treatment Market Size & CAGR (2025-2032)

• North America (Tumor Types, Treatment Products, Sites, End Uses)
  • US
  • Canada
• Europe (Tumor Types, Treatment Products, Sites, End Uses)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Types, Treatment Products, Sites, End Uses)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchison MediPharma Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AVEO Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSynthema Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations